E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 19.1 |
E.1.2 | Level | SOC |
E.1.2 | Classification code | 10010331 |
E.1.2 | Term | Congenital, familial and genetic disorders |
E.1.2 | System Organ Class | 10010331 - Congenital, familial and genetic disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the safety and tolerability of lumacaftor/ivacaftor (LUM/IVA) combination therapy in subjects 12 years and older with cystic fibrosis (CF) and advanced lung disease and who are homozygous for the F508del mutation on the CF transmembrane conductance regulator (CFTR) gene |
|
E.2.2 | Secondary objectives of the trial |
To evaluate the efficacy of LUM/IVA combination therapy |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Males and females, 12 years of age and older on the date of informed consent or, where appropriate, date of assent. •Homozygous for the F508del-CFTR mutation; historical genotype must be documented in the participant's source documents. • Percent predicted FEV1 <40 of adjusted for age, sex, and height at Screening • Able to understand and comply with protocol requirements, restrictions, and instructions and likely to complete the study as planned (as judged by the investigator). |
|
E.4 | Principal exclusion criteria |
•Participant currently receiving invasive mechanical ventilation. •History of any comorbidity that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the participant •Any clinically significant laboratory abnormalities at screening that would interfere with the study assessments or pose an undue risk for the subject •A 12-lead electrocardiograms (ECG) demonstrating QTcF >450 msec at Screening •History of solid organ or hematological transplantation •History of alcohol or drug abuse in the past year •Ongoing or prior participation in an investigational drug study (including studies investigating lumacaftor and/or ivacaftor) within 30 days of screening. •Use of strong inhibitors, moderate inducers, or strong inducers of CYP3A •Pregnant and nursing females: Females of childbearing potential must have a negative pregnancy test at Screening and Day 1. •Sexually active subjects of reproductive potential who are not willing to follow the contraception requirements •Use of beta blockers or the equivalent at Screening.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
• Safety and tolerability assessments based on adverse events, clinical laboratory values (hematology and serum chemistry), and standard 12 lead electrocardiograms (ECGs) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
- Baseline up to 28 days after the last dose (up to Week 28) |
|
E.5.2 | Secondary end point(s) |
• Absolute change from baseline in percent predicted forced expiratory volume in 1 second (ppFEV1) at each visit up to Week 24 • Absolute change from baseline in FEV1 (in Liters [L]) at each visit up to week 24 • Total number of days participants received intravenous (IV) antibiotics for pulmonary exacerbations through week 24 • Number of hospitalizations (all causes) participants had • Absolute change from baseline to average of Day 15 and Week 4 measurements in sweat chloride • Absolute change from baseline in Cystic Fibrosis Questionnaire - Revised (CFQ-R) respiratory domain score through week 24 |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
- Baseline, through Week 24 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
Will this trial be conducted at a single site globally?
| No |
E.8.4 | Will this trial be conducted at multiple sites globally? | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.2 | Trial being conducted completely outside of the EEA | Yes |
E.8.6.3 | Specify the countries outside of the EEA in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 7 |
E.8.9.2 | In all countries concerned by the trial days | 16 |